Propofol

Introduction Overview

Generic Name

Propofol

Brand Name

Diprivan, Propoven

Dosage Form

Intravenous emulsion for injection

Drug Class

General anesthetics

Pharmacokinetics

Absorption:
Propofol is administered exclusively via intravenous injection due to its high lipophilicity and poor water solubility. After IV bolus administration, it rapidly distributes into highly perfused tissues including the brain, resulting in rapid onset of anesthesia typically within 30 seconds. The onset is fast because there is no absorption phase unlike oral or intramuscular routes. In continuous infusions, steady state levels are reached rapidly depending on infusion rate and duration.

Distribution:
Propofol exhibits a high volume of distribution (approximately 2-5 L/kg), indicative of extensive tissue uptake, particularly in the brain and highly perfused organs. It is approximately 95-99% protein bound, predominantly to albumin. The drug quickly crosses the blood-brain barrier producing hypnotic effects. Redistribution from central compartments to peripheral tissues leads to the relatively brief duration of single-dose sedation and anesthesia. The lipid solubility also explains its rapid redistribution and clearance.

Metabolism:
Propofol undergoes extensive hepatic metabolism primarily via conjugation with glucuronic acid to inactive propofol glucuronide and sulfate conjugates. Cytochrome P450 enzymes, including CYP2B6 and CYP2C9, contribute minimally to oxidative metabolism, producing hydroxylated metabolites that are then conjugated. Extrahepatic metabolism, such as in the lungs, also contributes significantly to clearance. Metabolic pathways are high-capacity and usually not saturated at therapeutic doses.

Elimination:
The metabolites of propofol are eliminated primarily via renal excretion, with less than 1% of the parent drug excreted unchanged in urine. The elimination half-life is multi-phasic; the initial distribution half-life is brief (~2-8 minutes), while the terminal elimination half-life ranges from 1 to 3 hours depending on duration of infusion. Prolonged infusions may increase half-life due to accumulation in peripheral compartments but clearance remains efficient under normal hepatic and renal function. The rapid clearance supports propofol’s use for procedures requiring quick recovery.

Dosage Forms

Available Dosage Forms:
Propofol is supplied for intravenous use as a sterile, oil-in-water white emulsion commonly formulated with 10% soybean oil, glycerol, and egg lecithin. It is available in vials or ampules for IV injection or infusion.

Dosages for Adults and Adolescents:
Induction of anesthesia: IV bolus of 2 to 2.5 mg/kg over 20 to 30 seconds is standard. Maintenance can be achieved with continuous infusion at 100 to 200 mcg/kg/min, titrated according to anesthetic depth. For sedation in intensive care, continuous infusion rates of 5 to 50 mcg/kg/min are commonly employed. Dosage adjustments depend on patient response, clinical context, and procedure duration.

Specific Patient Populations:
In pediatric patients two months and older, induction doses range from 2.5 to 3.5 mg/kg and maintenance doses from 125 to 300 mcg/kg/min, adjusted per sedation needs. Propofol should be used cautiously in the elderly, who may require lower doses due to decreased clearance and increased sensitivity. In patients with hepatic or renal impairment, no specific dose adjustment is generally needed, but close monitoring is essential due to possible altered pharmacodynamics. Propofol is contraindicated in patients allergic to eggs, egg products, soybeans, or soy products.

Clinical guidelines emphasize the use of propofol in controlled healthcare settings with monitoring of vital signs, including blood pressure, oxygen saturation, and respiratory status, due to risks of hypotension and respiratory depression.

Mechanism Of Action

Propofol primarily acts as a central nervous system depressant by potentiating the activity of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain. It binds to the beta subunit of the GABA-A receptor complex, enhancing GABA-mediated chloride ion influx into neurons. This increases neuronal membrane hyperpolarization, decreasing neuronal excitability and resulting in sedation, hypnosis, and anesthesia.

At the molecular level, propofol increases both the frequency and duration of chloride channel opening of GABA-A receptors, facilitating inhibitory postsynaptic potentials. This leads to suppressed cortical neuronal activity, producing rapid loss of consciousness. Additionally, propofol may exert mild NMDA receptor antagonism and inhibit sodium channels, further contributing to its anesthetic effects.

Cellularly, propofol’s modulation of synaptic transmission leads to decreased neuronal firing in thalamocortical circuits important for consciousness and sensory perception, accounting for its hypnotic and amnestic properties. Its rapid redistribution from the central nervous system into peripheral tissues explains its fast onset and recovery.

Clinically, propofol’s mechanism facilitates smooth induction and maintenance of anesthesia with rapid emergence. Unlike volatile anesthetics, propofol does not accumulate significantly, reducing postoperative nausea and cognitive dysfunction. Comparative studies reveal propofol has a favorable side effect profile compared to other intravenous anesthetics like barbiturates or etomidate, though it carries a risk of hypotension and respiratory depression requiring careful monitoring. Ongoing research evaluates its neuroprotective properties and effects on synaptic plasticity.

Pharmacological Actions

Rapid induction and maintenance of general anesthesia.
Sedation for mechanically ventilated patients in intensive care units.
Hypnotic effect via enhancement of GABA-A receptor activity.
Minimal analgesic activity; not used as a pain reliever.
Reduction of cerebral metabolic rate and intracranial pressure.
Minimal accumulation with short procedures due to rapid redistribution and metabolism.
Anti-emetic properties reducing postoperative nausea and vomiting.
Dose-dependent respiratory depression and hypotension effects.
Exhibits anti-convulsant properties at anesthetic doses.
Facilitates rapid recovery of cognitive function post anesthesia.
Lipid emulsion formulation provides energy source and requires monitoring in prolonged infusions.
Potential for propofol infusion syndrome with prolonged high-dose administration.
Decreases systemic and cerebral blood flow while maintaining cerebral autoregulation.
Negligible effects on histamine release, reducing allergic reaction risks.
Does not accumulate in skeletal muscle, enabling rapid redistribution.

Therapeutic Or Clinical Uses

Induction of general anesthesia for surgical procedures.
Maintenance of general anesthesia in operative settings.
Sedation of mechanically ventilated patients in intensive care units.
Sedation for diagnostic procedures requiring conscious or deep sedation.
Used in pediatric anesthesia in patients 2 months and older.
Adjunct to regional or local anesthesia techniques.
Facilitates smooth emergence from anesthesia with minimal postoperative nausea.
Used for conscious sedation in some endoscopic and minor surgical procedures.
Off-label uses include sedation in neurocritical care to reduce elevated intracranial pressure.
Anesthetic agent of choice for procedures requiring rapid patient recovery.
Provides amnestic effects during procedures without analgesia.
Used in cardiac anesthesia protocols due to favorable hemodynamic effects.
Supports sedation when rapid titratability and quick awakening are desired.
Alternative for patients with allergies to inhalational anesthetics.
Commonly preferred for its anti-emetic and anti-convulsant properties during anesthesia.

Side Or Adverse Effects

Hypotension due to systemic vasodilation and myocardial depression.
Respiratory depression leading to apnea, requiring airway management.
Pain or burning sensation at injection site during administration.
Bradycardia and arrhythmias due to cardiac conduction effects.
Propofol infusion syndrome characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure with prolonged high-dose infusions.
Allergic reactions, including anaphylaxis, especially in patients allergic to eggs, soy, or propofol.
Mild transient rash or pruritus during or after administration.
Nausea is less frequent compared to other anesthetics but can occur.
Headache and dizziness post-procedure.
Elevated triglycerides and lipemia with prolonged infusions due to lipid emulsion formulation.
Rare occurrence of bacterial infections if strict aseptic techniques are not followed due to lipid medium supporting microbial growth.
Myoclonus or involuntary muscle movements occasionally reported.
Hyperlipidemia in intensive care patients with extended infusions.
Injection site complications such as thrombophlebitis.
Potential for central nervous system depression leading to delayed awakening in sensitive individuals.

Precautions

Use with caution in patients with egg, egg product, soybean, or soy product allergies due to formulation components.
Monitor cardiovascular and respiratory function closely due to risk of hypotension and respiratory depression.
Avoid use in patients with severe cardiac dysfunction without proper monitoring.
Careful dosing and monitoring in elderly patients due to increased sensitivity and slower metabolism.
Consider risks in pediatric patients under 3 years due to potential neurodevelopmental effects.
Use cautiously in patients with epilepsy or seizure disorders; monitor for seizure activity.
Monitor lipid levels and renal function during prolonged continuous infusions.
Strict aseptic techniques are essential to prevent infections due to lipid emulsion vehicle.
Avoid co-administration with other CNS depressants without careful adjustment to reduce additive respiratory depression.
Assess hepatic and renal function as these can impact drug metabolism and clearance.
Careful evaluation required for use during pregnancy and lactation; effects on fetal brain development are uncertain.
Ensure availability of resuscitation equipment and trained personnel during administration.
Avoid abrupt discontinuation after prolonged infusion to prevent withdrawal effects.
Regular monitoring of acid-base status in ICU patients on long-term infusions.
Inform patients not to drive or operate machinery for at least 24 hours after administration due to sedation.

Warnings

Contraindicated in patients with known hypersensitivity to propofol or any of its components including eggs or soy products.
Propofol Infusion Syndrome, a rare but potentially fatal complication, can occur with prolonged high-dose infusions leading to metabolic acidosis, cardiac failure, rhabdomyolysis, and renal failure.
Use with extreme caution in patients with severe cardiac disease or hemodynamic instability due to risk of profound hypotension.
Risk of respiratory depression and apnea necessitates airway management readiness during administration.
Potential neurotoxicity in pediatric patients under 3 years with prolonged or repeated exposure; use only if benefit outweighs risk.
May cause severe injection site pain; local irritation is common.
Risk of bacterial contamination due to lipid emulsion—strict aseptic technique required to avoid sepsis.
Cross-sensitivity and allergic reactions possible in patients with egg and soy allergies.
Concomitant use with other CNS depressants enhances sedative and respiratory depressive effects.
Pregnancy Category B: Animal studies show potential risks to brain development; human data limited.
Breastfeeding mothers should minimize infant exposure; propofol clears rapidly but can pass into breast milk.
Do not use in unmonitored settings due to risk of sudden respiratory or cardiovascular compromise.
Careful titration required to avoid overdose and prolonged sedation.
Propofol does not provide analgesia; combine with analgesics as needed.
Patients must be monitored continuously with appropriate equipment during and after administration.

Contraindication

Known hypersensitivity to propofol or any component of the formulation.
Allergy to eggs, egg products, soybeans, or soy products.
Patients with disorders of fat metabolism due to lipid emulsion vehicle.
Use in patients with hemodynamic instability without intensive monitoring.
Contraindicated for intramuscular or subcutaneous use due to formulation properties.
Severe respiratory insufficiency without airway support available.
Propofol administration in untrained or unmonitored settings.
History of propofol infusion syndrome.
Known sensitivity to any diprivan or generic propofol formulations.
Neonates or infants under two months of age due to insufficient safety data.
Patients with severe bradycardia unresponsive to medical intervention.
Use with caution or avoid concomitant use with other agents causing severe CNS depression if monitoring unavailable.
Individuals with metabolic acidosis in the setting of intensive care longer than 48 hours.
Patients receiving concomitant sedative-hypnotics or anesthetics without dose adjustment.
Known or suspected increased intracranial pressure unless under expert care.

Drug Interactions

Additive CNS and respiratory depression when combined with other sedatives, narcotics, anesthetics, muscle relaxants, or CNS depressants.
Caution with concomitant use of valproic acid which may exacerbate CNS depression.
May potentiate hypotensive effects of antihypertensive agents or vasodilators.
Enhanced sedative and respiratory depressant effects with benzodiazepines.
Potential interaction with opioids leading to increased risk of apnea and bradycardia.
Certain anticonvulsants may affect plasma levels of propofol requiring dose adjustment.
Avoid concomitant use with other drugs metabolized by CYP2B6 and CYP2C9 due to possible metabolic interaction.
Caution when used with neuromuscular blocking agents as combined respiratory depression effects may occur.
Interaction with alcohol potentiates sedative and depressant effects.
No significant interaction with non-steroidal anti-inflammatory drugs (NSAIDs).
Potential for increased sedation when combined with antihistamines or antipsychotics.
Concurrent use with anesthetic gases requires careful dosing and monitoring.
Additive vasodilation effects with nitric oxide donors or PDE5 inhibitors.
May interfere with metabolism of drugs causing arrhythmias, enhancing cardiac effects.
Interactions with herbal supplements such as kava or valerian increasing CNS depression.

Preparations Of The Drug

Propofol injectable emulsion 10 mg/mL (1%) in 20 mL, 50 mL, and 100 mL vials or ampules.
Formulated as a sterile, non-pyrogenic oil-in-water emulsion with 10% soybean oil, glycerol, and egg lecithin.
Preservative-free formulations for single-use vials to reduce infection risk.
Multi-dose vials with antimicrobial preservatives available in some markets.
Lipid emulsion vehicle provides energy and stable dispersion of propofol molecule.
Supplied in glass or plastic containers compatible with IV administration.
Requires storage under refrigerated conditions, protected from light.
Should be used immediately after opening or discarded due to risk of bacterial contamination.
Administered exclusively by intravenous route using syringe or infusion pump.
No oral, intramuscular, or subcutaneous preparations available clinically.
Special formulations for ICU sedation with capacity for continuous infusion pumps.
Compatible with standard IV fluids and commonly used infusion sets after thorough mixing.
Requires trained healthcare professional for preparation and administration due to risks.
Approved commercial preparations branded as Diprivan and Propoven among others.
Packaging includes appropriate labeling regarding allergens due to egg and soy content.